Skip to main content
DYN
NASDAQ Life Sciences

Major Shareholder Atlas Venture Files Intent to Sell Additional $2.15M in Stock Amidst Ongoing Distribution

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$21.32
Mkt Cap
$3.515B
52W Low
$8.06
52W High
$25
52W Position info
165% above low
Off High info
15% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

DYN has more than doubled off its 52-week low of $8.06.

Summary

Atlas Venture, a major institutional investor, plans to sell an additional $2.15 million in Dyne Therapeutics stock, continuing a trend of over $41 million in sales by its entities in the last three months.


Key Events · Ownership and Investor Activity · DYN

  • Proposed Stock Sale

    Atlas Venture Fund XI, LP intends to sell 102,969 shares of common stock, valued at approximately $2.15 million.

  • Ongoing Distribution by Major Shareholder

    This proposed sale is part of a larger pattern, with Atlas Venture entities having sold over $41 million in Dyne Therapeutics shares in the past three months, contributing to a net insider distribution of over $51 million in the last 90 days.

  • Institutional Selling Pressure

    The continued significant selling by a major institutional shareholder could create an overhang on the stock price.


Analysis · DYN · Life Sciences

Atlas Venture, a significant institutional shareholder, has filed a Form 144 indicating its intent to sell an additional $2.15 million worth of common stock. This proposed sale follows a pattern of substantial distribution by Atlas Venture entities, which have sold over $41 million in Dyne Therapeutics shares in the past three months. This ongoing selling pressure from a major investor could weigh on investor sentiment.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DYN was trading at $21.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $8.06 to $25.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DYN - Latest Insights

DYN
Nov 05, 2026, 7:25 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $18.63
Real-time Price: $17.99 info
Change: -$0.640 (-3%) info
Market Cap: $3.371B info
DYN
Sep 29, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.78
Real-time Price: $17.99 info
Change: +$2.21 (+14%) info
Market Cap: $3.371B info
DYN
Sep 29, 2026, 4:05 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $15.78
Real-time Price: $17.99 info
Change: +$2.21 (+14%) info
Market Cap: $3.371B info
DYN
Aug 17, 2026, 5:30 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $26.15
Real-time Price: $17.99 info
Change: -$8.16 (-31%) info
Market Cap: $3.371B info
DYN
Aug 14, 2026, 5:47 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $25.94
Real-time Price: $17.99 info
Change: -$7.95 (-31%) info
Market Cap: $3.371B info